Site Members can sign up for company wide alerts
Investigation Overview
December 5, 2014 (Update) - On July 22, 2014, Puma Biotechnology Inc announced positive top line results from the Phase III clinical trial of Puma's investigational breast cancer drug, PB272 (neratinib). Puma Biotechnology Inc said that based on the results from the ExteNET study, Puma plans to file for regulatory approval of neratinib in the extended adjuvant setting in the first hal...
You must register (for free) or login to view the entire investigation.